The estimated Net Worth of Frank Bedu Addo is at least $5.27 million dollars as of 2 December 2022. Frank Addo owns over 219,535 units of PDS Biotechnology stock worth over $2,684,755 and over the last 5 years he sold PDSB stock worth over $0. In addition, he makes $2,583,760 as President, Chief Executive Officer et Director at PDS Biotechnology.
Sign up
Frank Addo PDSB stock SEC Form 4 insiders trading
Frank has made over 2 trades of the PDS Biotechnology stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 219,535 units of PDSB stock worth $1,442,345 on 2 December 2022.
The largest trade he's ever made was exercising 219,535 units of PDS Biotechnology stock on 2 December 2022 worth over $1,442,345. On average, Frank trades about 38,958 units every 76 days since 2019. As of 2 December 2022 he still owns at least 866,050 units of PDS Biotechnology stock.
You can see the complete history of Frank Addo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Frank Bedu-Addo biography
Dr. Frank Bedu-Addo Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Bedu-Addo has served as President and CEO of PDS since its inception in 2005. Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the oversight, development and implementation of both operational and drug development strategies in both large organizations and emerging biotechnology companies. Dr. Bedu-Addo was a member of the senior executive team at KBI BioPharma, Inc. As Vice President of Drug Development, he oversaw all business and drug development operations. Before his tenure at KBI, he successfully started and managed Cardinal Health’s East Coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions, he contributed to the development of numerous drugs, including antiviral and anticancer products. Dr. Bedu-Addo obtained both his M.S. in Chemical Engineering and Ph.D. in Pharmaceutics from the University of Pittsburgh.
What is the salary of Frank Addo?
As the President, Chief Executive Officer et Director of PDS Biotechnology, the total compensation of Frank Addo at PDS Biotechnology is $2,583,760. There are no executives at PDS Biotechnology getting paid more.
How old is Frank Addo?
Frank Addo is 55, he's been the President, Chief Executive Officer et Director of PDS Biotechnology since 2020. There are 12 older and 2 younger executives at PDS Biotechnology. The oldest executive at PDS Biotechnology Corporation is Richard Sykes, 78, who is the Independent Director.
What's Frank Addo's mailing address?
Frank's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, SUITE 300, FLORHAM PARK, NJ, 07932.
Insiders trading at PDS Biotechnology
Over the last 5 years, insiders at PDS Biotechnology have traded over $0 worth of PDS Biotechnology stock and bought 54,275 units worth $476,657 . The most active insiders traders include Gregory Gene Freitag, James J Loughlin et Kamil Ali Jackson. On average, PDS Biotechnology executives and independent directors trade stock every 67 days with the average trade being worth of $126,706. The most recent stock trade was executed by Frank Bedu Addo on 2 December 2022, trading 219,535 units of PDSB stock currently worth $1,442,345.
What does PDS Biotechnology do?
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
What does PDS Biotechnology's logo look like?
Complete history of Frank Addo stock trades at PDS Biotechnology
PDS Biotechnology executives and stock owners
PDS Biotechnology executives and other stock owners filed with the SEC include:
-
Frank Bedu-Addo,
President, Chief Executive Officer, Director -
Dr. Frank K. Bedu-Addo Ph.D.,
Pres, CEO & Director -
Gregory Conn,
Chief Scientific Officer -
Lauren V. Wood M.D.,
Chief Medical Officer -
Dr. Gregory L. Conn,
Chief Scientific Officer -
Gregory Freitag,
Independent Director -
DeLyle Bloomquist,
Independent Director -
Stephen Glover,
Independent Chairman of the Board -
Richard Sykes,
Independent Director -
Otis Brawley,
Director -
Deanne Randolph,
Investor Relations -
Kamil Ali-Jackson,
Independent Director -
Ilian Iliev,
Director -
Lauren Wood,
Chief Medical Officer -
Michael King,
Interim Chief Financial Officer -
Janetta Trochimiuk,
Controller -
Dr. Mark Baxter Ph.D.,
Sr. VP of Global Quality -
Hillary Yegen,
VP of Legal -
Dr. Joe J. Dervan,
VP of R&D -
Matthew C. Hill CPA,
CFO & Principal Accounting Officer -
Matthew C Hill,
Chief Financial Officer -
James J Loughlin,
Director -
Voorhees Seth Van,
Chief Financial Officer -
Lars Boesgaard,
Chief Financial Officer -
Spencer D. Brown,
Senior VP, General Counsel -
Kirk V. Shepard,
Chief Medical Officer -
Stephan Toutain,
Chief Operations Officer